Saarland University Hospital

At Saarland University Hospital in Homburg, clinical research is strongly centered on pediatric hematology and pediatric oncology, with a broad mix of studies aimed at improving outcomes for children and adolescents with blood cancers and solid tumors. The trials focus on testing new treatment strategies, refining standard care, and improving long-term survival and disease control.

• Studies in acute lymphoblastic leukemia, acute myeloid leukemia, and lymphoblastic lymphoma are evaluating ways to improve survival and reduce relapse risk.
• Ewing sarcoma, medulloblastoma, neuroblastoma, and other childhood tumors are being investigated to optimize therapy and support better cancer control.
• Several trials explore whether adding targeted or immune-based treatments can make standard regimens more effective in high-risk pediatric cancers.

This research environment brings together a large investigator team and a wide range of studies designed to advance safer, more effective treatment approaches for young patients with hematologic malignancies and solid tumors.

A major part of the site’s portfolio addresses hematologic malignancies, including lymphoma, leukemia, and myelodysplastic syndromes. These trials are focused on evaluating new combinations, improving remission rates, and finding better options for patients with relapsed, refractory, or high-risk disease.

• Diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and chronic lymphocytic leukemia are key areas of study.
• Research in acute myeloid leukemia and related disorders aims to improve response depth and long-term disease control.
• Some studies examine treatment strategies around allogeneic hematopoietic cell transplantation and graft-versus-host disease.

The overall goal is to strengthen treatment effectiveness while improving tolerability for patients with complex blood cancers and transplant-related complications.

The site also contributes to research in breast cancer, lung cancer, prostate cancer, and other advanced solid tumors. These studies often assess new targeted therapies or immunotherapy combinations to improve disease control and reduce recurrence.

• Hormone receptor-positive breast cancer, HER2-positive breast cancer, and triple-negative breast cancer are prominent areas of investigation.
• Non-small cell lung cancer and small cell lung cancer trials are testing approaches to improve survival in earlier and advanced disease.
• Prostate cancer, cervical cancer, and colorectal cancer studies focus on improving treatment effectiveness and operability.

Overall, these trials aim to refine systemic treatment and expand options for patients with difficult-to-treat solid tumors.

Clinical trials at the site extend beyond cancer into neurology, ophthalmology, and rare diseases. This includes studies of neurodegenerative conditions, vision disorders, and inherited or uncommon disorders where better diagnosis or treatment is still needed.

• Alzheimer’s disease, Parkinson’s disease, and chronic inflammatory demyelinating polyneuropathy are being studied to improve symptom control and disease progression.
• Fuchs endothelial corneal dystrophy, neurotrophic keratopathy, and retinal artery occlusion trials focus on preserving or restoring vision.
• Hemophilia A, hemophilia B, Turner syndrome, and growth-related disorders reflect the site’s interest in rare and inherited conditions.

These studies are designed to test new therapies, improve functional outcomes, and support better care for patients with neurologic, eye, and genetic disorders.

The research portfolio also includes important work in cardiovascular disease, liver disease, metabolic disorders, and respiratory disease. These trials aim to improve treatment options for common chronic illnesses as well as severe conditions with limited effective therapies.

• Heart failure, hypertension, and pulmonary arterial hypertension are being studied to improve disease control and functional capacity.
• NASH, MASH, and cirrhosis trials focus on slowing progression and improving liver-related outcomes.
• Asthma, pulmonary fibrosis, and COPD studies address breathing symptoms and long-term respiratory health.

In these areas, the trials are mainly evaluating whether new treatments can better manage chronic disease burden and improve everyday quality of life.

Another strong theme is research in immune-mediated, inflammatory, and metabolic diseases. These studies look for better ways to control persistent symptoms, reduce disease activity, and support more durable responses.

• Crohn’s disease, atopic dermatitis, and chronic graft-versus-host disease are among the inflammatory conditions under study.
• Type 2 diabetes, iron deficiency, and other metabolic or nutritional disorders are also represented.
• Several trials investigate targeted or immune-based approaches to improve treatment effectiveness in complex chronic conditions.

Together, these studies reflect a broad effort to improve management of immune system and metabolic disorders through more precise and better-tolerated therapies.